ArticleAdvances in therapy2018
A Charter to Improve Patient Care in Severe Asthma.
Article in Advances in therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management.American journal of respiratory and critical care medicine · 2020Pooled it
- Measured and perceived affordability of asthma medications and their associations with medication adherence among adult patients in Ethiopia: A cross-sectional study.Exploratory research in clinical and social pharmacy · 2026Article
- Health system characteristics and evidence-based asthma care.Frontiers in allergy · 2025Article
- Comparison of Asthma Phenotypes in Severe Asthma Cohorts (SARP, U-BIOPRED, ProAR and COREA) From 4 Continents.Allergy, asthma & immunology research · 2024Article
- A survey of severe asthma in Canada: results from the CASCADE practice reflective program.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Quality of life and work functionality in severe asthma patients: the impact of biological therapies.Journal of occupational medicine and toxicology (London, England) · 2024Article
- Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA.Frontiers in allergy · 2024Article
- Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis.Pragmatic and observational research · 2024Article
- Vocal cord dysfunction/inducible laryngeal obstruction-2022 Melbourne Roundtable Report.Respirology (Carlton, Vic.) · 2023Review
- A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma.Advances in therapy · 2023Review
- What bothers severe asthma patients most? A paired patient-clinician study across seven European countries.ERJ open research · 2023Article
- The use of systemic corticosteroids in asthma management in Latin American countries.The World Allergy Organization journal · 2023Review
- A Meta-Analysis on Predictors of Mortality Among Patients Hospitalized for Acute Exacerbation of Asthma.Cureus · 2023Review
- Transcriptomics reveals a distinct metabolic profile in T cells from severe allergic asthmatic patients.Frontiers in allergy · 2023Article
- Unmet Need for Oral Corticosteroids Use and Exacerbations of Asthma in Primary Care in Taiwan.Biomedicines · 2022Article
- A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.Advances in therapy · 2022Article
- Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group.The World Allergy Organization journal · 2022Review
- Retrospective cross-sectional study of asthma severity in adult patients at the Jimma Medical Center, Ethiopia.Scientific reports · 2022Article
- Patients with Severe Uncontrolled Asthma: Perception of Asthma Control and its Management.Pulmonary therapy · 2022Article
- Improving Care in Eosinophil-Associated Diseases: A Charter.Advances in therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma is a subtype of asthma that is difficult to treat and control. By conservative estimates, severe asthma affects approximately 5-10% of patients with asthma worldwide. Severe asthma impairs patients' health-related quality of life, and patients are at risk of life-threatening asthma attacks. Severe asthma also accounts for the majority of health care expenditures associated with asthma. Guidelines recommend that patients with severe asthma be referred to a specialist respiratory team for correct diagnosis and expert management. This is particularly important to ensure that they have access to newly available biologic treatments. However, many patients with severe asthma can suffer multiple asthma attacks and wait several years before they are referred for specialist care. As global patient advocates, we believe it is essential to raise awareness and understanding for patients, caregivers, health care professionals, and the public about the substantial impact of severe asthma and to create opportunities for improving patient care. Patients should be empowered to live a life free of symptoms and the adverse effects of traditional medications (e.g., oral corticosteroids), reducing hospital visits and emergency care, the loss of school and work days, and the constraints placed on their daily lives. Here we provide a Patient Charter for severe asthma, consisting of six core principles, to mobilize national governments, health care providers, payer policymakers, lung health industry partners, and patients/caregivers to address the unmet need and burden in severe asthma and ultimately work together to deliver meaningful improvements in care.
fundingAstraZeneca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.